Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.
- DOI
- 10.1016/s0140-6736(22)02324-8
- Published
- 2023 Jan 7
- Container
- Lancet (London, England)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/s0140-6736-22-02324-8,
title = {Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.},
author = {Thompson GR 3rd and Soriano A and Cornely OA and Kullberg BJ and Kollef M and Vazquez J and Honore PM and Bassetti M and Pullman J and Chayakulkeeree M and Poromanski I and Dignani C and Das AF and Sandison T and Pappas PG and ReSTORE trial investigators},
year = {2023},
journal = {Lancet (London, England)},
doi = {10.1016/s0140-6736(22)02324-8},
url = {https://doi.org/10.1016/s0140-6736(22)02324-8}
}RIS
TY - JOUR TI - Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial. AU - Thompson GR 3rd AU - Soriano A AU - Cornely OA AU - Kullberg BJ AU - Kollef M AU - Vazquez J AU - Honore PM AU - Bassetti M AU - Pullman J AU - Chayakulkeeree M AU - Poromanski I AU - Dignani C AU - Das AF AU - Sandison T AU - Pappas PG AU - ReSTORE trial investigators PY - 2023 JO - Lancet (London, England) DO - 10.1016/s0140-6736(22)02324-8 UR - https://doi.org/10.1016/s0140-6736(22)02324-8 ER -
APA
3rd, T. G., A, S., OA, C., BJ, K., M, K., J, V., PM, H., M, B., J, P., M, C., I, P., C, D., AF, D., T, S., PG, P., & investigators, R. T. (2023). Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trial.. Lancet (London, England). https://doi.org/10.1016/s0140-6736(22)02324-8
Source records
- pubmed · retrieved 2026-09-25T22:25:18.243Z